top of page
ADELA
ELACESTRANT + EVEROLIMUS IN PATIENTS WITH ER+/HER2-, ESR1MUT, ADVANCED BREAST CANCER PROGRESSING ON ENDOCRINE THERAPY AND CDK4/6 INHIBITORS
CLINICAL TRIAL DETAILS
A RANDOMIZED PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ELACESTRANT PLUS EVEROLIMUS VERSUS ELACESTRANT IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE, ESR1-MUTATED, ADVANCED BREAST CANCER PROGRESSING TO ENDOCRINE THERAPY AND CDK4/6 INHIBITORS.
ADELA AT CLINICALTRIALS.GOV
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
ER+/HER2- ABC
110
240
III
Austria, Brazil, Czech Republic, Spain, France, Greece, Italy, Germany, UK
Recruiting
TRIAL OVERVIEW
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
TRIAL SITES
-
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page